Octant Receives FDA Orphan Drug Designation for OCT-980 for the Treatment of Retinitis Pigmentosa

Octant Receives FDA Orphan Drug Designation for OCT-980 for the Treatment of Retinitis Pigmentosa

EMERYVILLE, Calif.--(BUSINESS WIRE)--Oct 27, 2026-

FDA grants orphan drug status to Octant's OCT-980 for RP

The regulatory status specifically includes rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP), the indication for which the candidate is presently being evaluated. Orphan status is granted to support the The post FDA grants orphan drug status to Octant’s OCT-980 for RP appeared first on Pharmaceutical Business review.